Skip to main content

Advertisement

SpringerLink
Log in

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

The purpose of this study was to compare changes in bone mineral density (BMD) in premenopausal patients with node-positive early breast cancer treated with goserelin (Zoladex) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients (n=1640) were randomized to goserelin (3.6 mg every 28 days for 2 years) or CMF (six×28-day cycles) treatment. In a protocoled sub-study involving 96 patients from eight centers (goserelin: n=53; CMF: n=43), lumbar spine (L2–L4) and femoral neck BMD were assessed by dual X-ray absorptiometry at baseline and then annually for 3 years. At the end of the 2-year goserelin-treatment period, mean BMD losses for goserelin-treated and CMF-treated patients were −10.5% and −6.5% (P=0.0005) for lumbar spine and −6.4% and −4.5% (P=0.04) for femoral neck, respectively. At 3 years, partial recovery of BMD was observed in goserelin recipients. In contrast, mean BMD losses for the CMF group indicated persistent BMD loss. No significant differences in BMD were observed between groups at the 3-year assessment of the spine or femoral neck. In the CMF group, based on amenorrhea status at 48 weeks, BMD losses at the lumbar spine were greater for amenorrheic than non-amenorrheic patients. Ovarian suppression resulting in amenorrhea was closely related to BMD loss in both treatment groups. Overall, patients who received CMF did not show recovery of BMD throughout follow-up, whereas partial recovery was observed 1 year after cessation of goserelin therapy, associated with the return of ovarian function in the majority of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Del Mastro L, Venturini M, Sertoli MR, Rosso R (1997) Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 43:183–190

    Article  PubMed  Google Scholar 

  2. Pagani O, O’Neill A, Castiglione M, Gelber RD, Goldhirsh A, Rudenstam CM et al. (1998) Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34:632–640

    Article  PubMed  Google Scholar 

  3. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M et al. (2002) Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study. J Clin Oncol 20:4628–4635

    Article  CAS  PubMed  Google Scholar 

  4. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P et al. (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718–2727

    CAS  PubMed  Google Scholar 

  5. Jakesz R, Hausmaninger H, Samonigg H et al. (2001) Complete endocrine blockade with tamoxifen and goserelin is superior to CMF in the adjuvant treatment of premenopausal, lymph node-positive and -negative patients with hormone-responsive breast cancer. Breast 10:S10 (abstract S26)

    Google Scholar 

  6. Davidson N, O’Neill A, Vukov A, Osborne S, Martino D, White M.D (1999) Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup trial. Proc ASCO 18:67a (abstract 249)

    Google Scholar 

  7. Baum M, Houghton J, Odling-Smee W et al. (2001) Adjuvant Zoladex in premenopausal patients with early breast cancer: results from the ZIPP trial. Breast 10:S32–S33 (abstract P64)

    Google Scholar 

  8. de Haes H and the ZEBRA Trialists Group (2000) Comparison of quality of life in pre/perimenopausal women treated with Zoladex or CMF as adjuvant therapy for the management of node-positive early breast cancer: results from the ZEBRA study. Breast Pharmacokinet 39:27–48

    Google Scholar 

  9. Olschewski M, de Haes H (2001) The ZEBRA study: early benefits in quality of life in goserelin-treated vs CMF-treated pre/perimenopausal patients with node-positive early breast cancer. Eur J Cancer 37:S40 (abstract Q115)

    Article  Google Scholar 

  10. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T et al. (2002) Randomized adjuvant trial of tamoxifen plus goserelin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer. J Clin Oncol 20:4621–4627

    Article  CAS  PubMed  Google Scholar 

  11. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Aldrighetti D et al. (2001) CMF vs tamoxifen (TAM) plus ovarian suppression (OS) as adjuvant treatment of ER-positive (ER+) pre/perimenopausal breast cancer (BCA) patients. Breast 10:S32 (abstract P62)

    Google Scholar 

  12. Trevisan C, Ortolani S, Bianchi ML, Caraceni MP, Ulivieri FM, Gandolini G, Polli EE (1991) Age, time since menopause, and body parameters as determinants of female spinal bone mass: a mathematical model. Calcif Tiss Int 49:1–5

    CAS  Google Scholar 

  13. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK et al. (1993) Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 341:72–75

    CAS  PubMed  Google Scholar 

  14. Tannirandorn P, Epstein S (2000) Drug-induced bone loss. Osteoporos Int 11:637–659

    Article  PubMed  Google Scholar 

  15. Fogelman I (1996) The effects of estrogen deficiency on the skeleton and its prevention. Br J Obstet Gynaecol 103 (suppl 14):5–9

    PubMed  Google Scholar 

  16. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341–1347

    CAS  PubMed  Google Scholar 

  17. Melton LJ, Thamer M, Ray NF, Chan JK, Chesnut CH, Einhorn TA et al. (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23

    PubMed  Google Scholar 

  18. Peterson JA (2001) Osteoporosis overview. Geriatr Nurs 22:17–21

    Article  CAS  PubMed  Google Scholar 

  19. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405–410

    CAS  PubMed  Google Scholar 

  20. Steiger P (1995) Standardization of spine BMD measurements. J Bone Miner Res 10:1602–1603

    PubMed  Google Scholar 

  21. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K et al. (1994) Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 9:1503–1514

    CAS  PubMed  Google Scholar 

  22. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308–310

    CAS  PubMed  Google Scholar 

  23. Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN (1998) Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 16:6–11

    CAS  PubMed  Google Scholar 

  24. Delmas PD, Fontana A (1998) Bone loss induced by cancer treatment and its management. Eur J Cancer 34:260–262

    Article  CAS  PubMed  Google Scholar 

  25. Fogelman I (1992) Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 57:715–724

    CAS  PubMed  Google Scholar 

  26. Paoletti AM, Serra GG, Cagnacci A, Vacca AM, Guerriero S, Solla E, Melis GB (1996) Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 65:707–710

    PubMed  Google Scholar 

  27. Taga M, Minaguchi H (1996) Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 75:162–165

    CAS  PubMed  Google Scholar 

  28. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A et al. (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704–708

    Article  CAS  PubMed  Google Scholar 

  29. Namer M, Jonat W, Kaufmann M, Blamey R, Cuzick J, Fogelman I et al. (2002) Survival data from the ZEBRA study. Ann Oncol 13 (suppl 5):38 (abstract 135P)

    Google Scholar 

Download references

Acknowledgements

The ZEBRA study is supported by a grant from AstraZeneca, Macclesfield, UK. Participating investigators: M. Geberth, Heidelberg, Germany; B. Lisboa, Hamburg, Germany; A.X. Izquierdo, Gerona, Spain; P. Firat, Ankara, Turkey; S.J. Leinster, Liverpool, UK.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Guy’s, Kings and St Thomas’ Hospital Medical School, London, SE1 9RT, UK

    I. Fogelman & G. M. Blake

  2. Nottingham Hospital, Nottingham, UK

    R. Blamey

  3. AstraZeneca, Macclesfield, UK

    M. Palmer & W. Wilpshaar

  4. Institute fur Medizinische Biometrie und Informatik, University Hospital, Freiburg, Germany

    M. Schumacher

  5. Clinic Sainte Catherine, Avignon, France

    D. Serin

  6. Christie Hospital, Manchester, UK

    A. Stewart

Authors
  1. I. Fogelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. M. Blake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Blamey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Sauerbrei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Serin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. Wilpshaar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Fogelman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fogelman, I., Blake, G.M., Blamey, R. et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14, 1001–1006 (2003). https://doi.org/10.1007/s00198-003-1508-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1508-y

Keywords

Search

Navigation